Agilent Technologies Inc (A)vsCareDx Inc (CDNA)
A
Agilent Technologies Inc
$172.79
-0.03%
HEALTHCARE · Cap: $44.12B
CDNA
CareDx Inc
$63.68
+3.76%
HEALTHCARE · Cap: $3.17B
Smart Verdict
WallStSmart Research — data-driven comparison
Agilent Technologies Inc generates 1509% more annual revenue ($7.37B vs $458.09M). CDNA leads profitability with a 24.2% profit margin vs 19.5%. CDNA trades at a lower P/E of 26.1x. A earns a higher WallStSmart Score of 63/100 (C+).
A
Buy63
out of 100
Grade: C+
CDNA
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.8%
Fair Value
$77.73
Current Price
$172.79
$95.06 premium
Margin of Safety
+68.0%
Fair Value
$61.69
Current Price
$63.68
$1.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 25.6%
Revenue surging 52.2% year-over-year
Conservative balance sheet, low leverage
Keeps 24 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Grey zone — moderate risk
Weak financial health signals
Moderate valuation
0.0% earnings growth
Operating margin of 0.2%
ROE of -2.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on Operating Margin. Profitability is solid with margins at 19.5% and operating margin at 25.6%. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.2% and operating margin at 0.2%. Revenue growth of 52.2% demonstrates continued momentum.
Bear Case : A
The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, EPS Growth, Operating Margin.
Key Dynamics to Monitor
A profiles as a mature stock while CDNA is a growth play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.43 — expect wider price swings.
CDNA is growing revenue faster at 52.2% — sustainability is the question.
A generates stronger free cash flow (439M), providing more financial flexibility.
Bottom Line
A scores higher overall (63/100 vs 53/100), backed by strong 19.5% margins. CDNA offers better value entry with a 68.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?